Could we expect new praziquantel derivatives? A meta pharmacometrics/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature

References

• L.D.P. Siqueira, D.A.F. Fontes, C.S.B. Aguilera, T.R.R. Timóteo, M.A. Ângelos, L.C.P.B.B. Silva, C.G. de Melo, L.A. Rolim, R.M.F. da Silva, and P.J.R. Neto, Schistosomiasis: Drugs used and treatment strategies, Acta Trop. 176 (2017), pp. 179–187. doi:10.1016/j.actatropica.2017.08.002.
   PubMed Web of Science ®Google Scholar
• WHO, Schistosomiasis. facts heet N°115 - Octobre 2017. Available at http://www.who.int/mediacentre/factsheets/fs115/en/.
   Google Scholar
• D.G. Colley, A.L. Bustinduy, W.E. Secor, and C.H. King, Human schistosomiasis, Lancet 383 (2014), pp. 2253–2264. doi:10.1016/S0140-6736(13)61949-2.
   PubMed Web of Science ®Google Scholar
• J. Kincaid-Smith, O. Rey, E. Toulza, A. Berry, and J. Boissier, Emerging schistosomiasis in Europe: A need to quantify the risks, Trends Parasitol. 33 (2017), pp. 600–609. doi:10.1016/j.pt.2017.04.009.
   PubMed Web of Science ®Google Scholar
• S. Brooker, A.C. Clements, and D.A. Bundy, Global epidemiology, ecology and control of soil-transmitted helminth infections, Adv. Parasitol. 62 (2006), pp. 221–261.
   PubMed Web of Science ®Google Scholar
• B. Gryseels, K. Polman, J. Clerinx, and L. Kestens, Human schistosomiasis, Lancet London Engl. 368 (2006), pp. 1106–1118. doi:10.1016/S0140-6736(06)69440-3.
   PubMed Web of Science ®Google Scholar
• Glossário-Esquistossomose. Available at http://portal.saude.gov.br/portal/saude/profissional/area.cfm?id_area=1551.
   Google Scholar
• 19th WHO model list of essential medicines. Available at http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.
   Google Scholar
• M.J. Doenhoff, D. Cioli, and J. Utzinger, Praziquantel: Mechanisms of action, resistance and new derivatives for schistosomiasis, Curr. Opin. Infect. Dis. 21 (2008), pp. 659–667. doi:10.1097/QCO.0b013e328318978f.
   PubMed Web of Science ®Google Scholar
• V.B.R. da Silva, B.R.K.L. Campos, J.F. de Oliveira, J.-L. Decout, and M.D.C.A. de Lima, Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine, Bioorg. Med. Chem. 25 (2017), pp. 3259–3277. doi:10.1016/j.bmc.2017.04.031.
   PubMed Web of Science ®Google Scholar
• J. Seubert, H. Thomas, P. Andrews, and M.P.G.M.B. Haftung. 2-Acyl-4-oxo-pyrazino-isoquinoline derivatives and process for the preparation thereof, Z. Arztl. Fortbild. 71 (1977), pp. 604–605.
   Google Scholar
• P. Andrews, H. Thomas, R. Pohlke, and J. Seubert, Praziquantel, Med. Res. Rev. 3 (1983), pp. 147–200. doi:10.1002/(ISSN)1098-1128.
   PubMed Web of Science ®Google Scholar
• C.H. King and A.A. Mahmoud, Drugs five years later: Praziquantel, Ann. Intern. Med. 110 (1989), pp. 290–296. doi:10.7326/0003-4819-110-4-290.
   PubMed Web of Science ®Google Scholar
• Y. Dong, J. Chollet, M. Vargas, N.R. Mansour, Q. Bickle, Y. Alnouti, J. Huang, J. Keiser, and J.L. Vennerstrom., Praziquantel analogs with activity against juvenile Schistosoma mansoni, Bioorg. Med. Chem. Lett. 20 (2010), pp. 2481–2484. doi:10.1016/j.bmcl.2010.03.001.
   PubMed Web of Science ®Google Scholar
• W. Duan, S. Qiu, Y. Zhao, H. Sun, C. Qiao, and C. Xia, Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum, Bioorg. Med. Chem. Lett. 22 (2012), pp. 1587–1590. doi:10.1016/j.bmcl.2011.12.133.
   PubMed Web of Science ®Google Scholar
• W. Wang, L. Wang, and Y.-S. Liang, Susceptibility or resistance of praziquantel in human schistosomiasis: A review, Parasitol. Res. 111 (2012), pp. 1871–1877. doi:10.1007/s00436-012-2938-2.
   PubMed Web of Science ®Google Scholar
• V. Salvador-Recatalà and R.M. Greenberg, Calcium channels of schistosomes: Unresolved questions and unexpected answers, Wiley Interdiscip. Rev. Membr. Transp. Signal. 1 (2012), pp. 85–93. doi:10.1002/wmts.19.
   PubMedGoogle Scholar
• M. Gnanasekar, A.M. Salunkhe, A.K. Mallia, Y.X. He, and R. Kalyanasundaram, Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni, Antimicrob. Agents Chemother. 53 (2009), pp. 1054–1060. doi:10.1128/AAC.01222-08.
   PubMed Web of Science ®Google Scholar
• J.J. Feng, H.F. Guo, M.Y. Yao, and S.H. Xiao, Effects of mebendazole, albendazole, and praziquantel on glutathione S-transferase and superoxide dismutase of Echinococcus granulosus cyst wall harbored in mice, Zhongguo Yao Li Xue Bao 16 (1995), pp. 297–300.
   Google Scholar
• M.H. El-Faham, M.M. Eissa, J.E. Igetei, E.I. Amer, S. Liddell, M.Z. El-Azzouni, and M.J. Doenhoff, Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens, PLoS Negl. Trop. Dis. 11 (2017), pp. e0005853. doi:10.1371/journal.pntd.0005853.
   PubMed Web of Science ®Google Scholar
• F. Angelucci, A. Basso, A. Bellelli, M. Brunori, L. Pica Mattoccia, and C. Valle, The anti-schistosomal drug praziquantel is an adenosine antagonist, Parasitology 134 (2007), pp. 1215–1221. doi:10.1017/S0031182007002600.
   PubMed Web of Science ®Google Scholar
• J.D. Chan, P.M. Cupit, G.S. Gunaratne, J.D. McCorvy, Y. Yang, K. Stoltz, T.R. Webb, P.I. Dosa, B.L. Roth, R. Abagyan, C. Cunningham, and J. Marchant, The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand, Nat. Commun. 8 (2017), pp. 1910. doi:10.1038/s41467-017-02084-0.
   PubMed Web of Science ®Google Scholar
• Cheminformatics models for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Available at https://www.hindawi.com/journals/tswj/2014/957107/.
   Google Scholar
• B.J. Neves, R.C. Braga, J.C.B. Bezerra, P.V.L. Cravo, and C.H. Andrade, In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni, PLoS Negl. Trop. Dis. 9 (2015), pp. e3435. doi:10.1371/journal.pntd.0003435.
   PubMed Web of Science ®Google Scholar
• L.G. Ferreira, G. Oliva, and A.D. Andricopulo, Target-based molecular modeling strategies for schistosomiasis drug discovery, Future Med. Chem. 7 (2015), pp. 753–764. doi:10.4155/fmc.15.21.
   PubMed Web of Science ®Google Scholar
• A. Zafar, S. Ahmad, A. Rizvi, and M. Ahmad, Novel non-peptide inhibitors against SmCL1 of Schistosoma mansoni: In silico elucidation, implications and evaluation via knowledge based drug discovery, PLoS ONE 10 (2015), pp. e0123996. doi:10.1371/journal.pone.0123996.
   PubMed Web of Science ®Google Scholar
• I. Akachukwu, O.O. Olubiyi, A. Kosisochukwu, M. C John, and N.N. Justina, Structure-based study of natural products with anti-schistosoma activity, Curr. Comput. Aided Drug Des. 13 (2017), pp. 91–100. doi:10.2174/1573409913666170119114859.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2017–2: Phase, Schrödinger, LLC, New York, NY, 2017.
   Google Scholar
• Schrödinger Release 2017–2: QikProp, Schrödinger, LLC, New York, NY, 2017.
   Google Scholar
• R Development Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2008.
   Google Scholar
• S. Guglielmo, D. Cortese, F. Vottero, B. Rolando, V.P. Kommer, D.L. Williams, R. Fruttero, and A. Gasco, New praziquantel derivatives containing no-donor furoxans and related furazans as active agents against Schistosoma mansoni, Eur. J. Med. Chem. 84 (2014), pp. 135–145. doi:10.1016/j.ejmech.2014.07.007.
   PubMed Web of Science ®Google Scholar
• L. Dong, W. Duan, J. Chen, H. Sun, C. Qiao, and C. Xia, An artemisinin derivative of praziquantel as an orally active antischistosomal agent, PLoS ONE 9 (2014), pp. e112163. doi:10.1371/journal.pone.0112163.
   PubMed Web of Science ®Google Scholar
• J. Yang, J. Boissier, J.-L. Chen, H. Yao, S. Yang, A. Rognon, and C. Qiao, Design, synthesis and biological evaluation of praziquantel and endoperoxide conjugates as antischistosomal agents, Future Med. Chem. 7 (2015), pp. 713–725. doi:10.4155/fmc.15.20.
   PubMed Web of Science ®Google Scholar
• M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. Spingler, J. Keiser, and G. Gasser, Ferrocenyl derivatives of the anthelmintic praziquantel: Design, synthesis, and biological evaluation, J. Med. Chem. 55 (2012), pp. 8790–8798. doi:10.1021/jm301077m.
   PubMed Web of Science ®Google Scholar
• M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. Spingler, R.B. Gasser, J. Keiser, and G. Gasser, [(η(6)-Praziquantel)Cr(CO)3] derivatives with remarkable in vitro anti-schistosomal activity, Chem. Weinh. Bergstr. Ger. 19 (2013), pp. 2232–2235.
   Google Scholar
• Y. Xie, Y. Li, Y. Wu, C. Liu, X. Li, X. Li, and X. Fan, Synthesis of fluorescent derivatives of praziquantel: Cell-imaging and interaction with Schistosoma japonicum cercariae, Org. Biomol. Chem. 11 (2013), pp. 5989–5993. doi:10.1039/c3ob41348a.
   PubMed Web of Science ®Google Scholar
• F. Ronketti, A.V. Ramana, X. Chao-Ming, L. Pica-Mattoccia, D. Cioli, and M.H. Todd, Praziquantel derivatives I: Modification of the aromatic ring, Bioorg. Med. Chem. Lett. 17 (2007), pp. 4154–4157. doi:10.1016/j.bmcl.2007.05.063.
   PubMed Web of Science ®Google Scholar
• M.M. Kamel, M.M. Anwar, A.M. Soliman, and H.F. Abdel-Hamid, In vitro antischistosomal evaluation of some newly synthesized praziquantel derivatives, Res. Chem. Intermed. 39 (2012), pp. 3417–3426. doi:10.1007/s11164-012-0854-9.
   Web of Science ®Google Scholar
• P.S. Sadhu, S.N. Kumar, M. Chandrasekharam, L. Pica-Mattoccia, D. Cioli, and V.J. Rao, Synthesis of new praziquantel analogues: Potential candidates for the treatment of schistosomiasis, Bioorg. Med. Chem. Lett. 22 (2012), pp. 1103–1106. doi:10.1016/j.bmcl.2011.11.108.
   PubMed Web of Science ®Google Scholar
• H. Liu, S. William, E. Herdtweck, S. Botros, and A. Dömling, MCR synthesis of praziquantel derivatives, Chem. Biol. Drug Des. 79 (2012), pp. 470–477. doi:10.1111/j.1747-0285.2011.01288.x.
   PubMed Web of Science ®Google Scholar
• L.K. Sharma, P.M. Cupit, T. Goronga, T.R. Webb, and C. Cunningham, Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel, Bioorg. Med. Chem. Lett. 24 (2014), pp. 2469–2472. doi:10.1016/j.bmcl.2014.04.014.
   PubMed Web of Science ®Google Scholar
• M.H. Abo-Ghalia and A.M. Soliman, Synthesis and study of the antischistosomal potency and induced biological parameters of a new 2-palmitoyl analogue of the universal antihelminthic praziquantel, Acta Pol. Pharm. 57 (2000), pp. 53–59.
   PubMedGoogle Scholar
• W.L. Wang, L.J. Song, X. Chen, X.R. Yin, W.H. Fan, G.P. Wang, C.X. Yu, and B. Feng, Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum, Molecules 18 (2013), pp. 9163–9178. doi:10.3390/molecules18089163.
   PubMed Web of Science ®Google Scholar
• Z. Wang, J. Chen, and C. Qiao, Praziquantel derivatives with antischistosomal activity: Aromatic ring modification, Chem. Biol. Drug Des. 82 (2013), pp. 216–225. doi:10.1111/cbdd.2013.82.issue-2.
   PubMed Web of Science ®Google Scholar
• Y. Zheng, L. Dong, C. Hu, B. Zhao, C. Yang, C. Xia, and D. Sun, Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum, Bioorg. Med. Chem. Lett. 24 (2014), pp. 4223–4226. doi:10.1016/j.bmcl.2014.07.039.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2017–2: Canvas, Schrödinger, LLC, New York, NY, 2017.
   Google Scholar
• W.L. Jorgensen, D. Maxwell, and J. Tirado-Rives, Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc. 118 (1996), pp. 11225–11236. doi:10.1021/ja9621760.
   Web of Science ®Google Scholar
• K.S. Watts, P. Dalal, R.B. Murphy, W. Sherman, R.A. Friesner, and J.C. Shelley, ConfGen: A conformational search method for efficient generation of bioactive conformers, J. Chem. Inf. Model. 50 (2010), pp. 534–546. doi:10.1021/ci100015j.
   PubMed Web of Science ®Google Scholar
• S.L. Dixon, A.M. Smondyrev, and S.N. Rao, PHASE: A novel approach to pharmacophore modeling and 3D database searching, Chem. Biol. Drug Des. 67 (2006), pp. 370–372. doi:10.1111/j.1747-0285.2006.00384.x.
   PubMed Web of Science ®Google Scholar
• S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, and R.A. Friesner, PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. methodology and preliminary results, J. Comput. Aided Mol. Des. 20 (2006), pp. 647–671. doi:10.1007/s10822-006-9043-5.
   PubMed Web of Science ®Google Scholar
• G. Schwarz, Estimating the dimension of a model, Ann. Stat. 6 (1978), pp. 461–464. doi:10.1214/aos/1176344136.
   Web of Science ®Google Scholar
• A. Borrego-Sánchez, C. Viseras, C. Aguzzi, and C.I. Sainz-Díaz, Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism, Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 92 (2016), pp. 266–275.
   PubMed Web of Science ®Google Scholar
• A.D. McNaught and A. Wilkinson, IUPAC. Compendium of Chemical Terminology, 2nd ed., The “Gold Book”, Blackwell Scientific Publications, Oxford, London, 1997.
   Google Scholar
• X.-Q. Li, A. Björkman, T.B. Andersson, L.L. Gustafsson, and C.M. Masimirembwa, Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data, Eur. J. Clin. Pharmacol. 59 (2003), pp. 429–442. doi:10.1007/s00228-003-0636-9.
   PubMed Web of Science ®Google Scholar
• C. Lerch and G. Blaschke, Investigation of the stereoselective metabolism of praziquantel after incubation with rat liver microsomes by capillary electrophoresis and liquid chromatography–mass spectrometry, J. Chromatogr. B. Biomed. Sci. Appl. 708 (1998), pp. 267–275. doi:10.1016/S0378-4347(97)00638-5.
   PubMed Web of Science ®Google Scholar
• H. Meier and G. Blaschke, Investigation of Praziquantel metabolism in isolated rat hepatocytes, J. Pharm. Biomed. Anal. 26 (2001), pp. 409–415. doi:10.1016/S0731-7085(01)00417-4.
   PubMed Web of Science ®Google Scholar
• A.J.B. Melo, Y. Iamamoto, A.P.J. Maestrin, J.R.L. Smith, M.D. Santos, N.P. Lopes, and P.S. Bonato, Biomimetic oxidation of praziquantel catalysed by metalloporphyrins, J. Mol. Catal. Chem. 226 (2005), pp. 23–31. doi:10.1016/j.molcata.2004.09.015.
   Google Scholar
• Z.S. Hendsch and B. Tidor, Do salt bridges stabilize proteins? A continuum electrostatic analysis, Protein Sci. Publ. Protein Soc. 3 (1994), pp. 211–226. doi:10.1002/pro.5560030206.
   PubMed Web of Science ®Google Scholar
• B.G. Tehan, E.J. Lloyd, M.G. Wong, W.R. Pitt, J.G. Montana, D.T. Manallack, and E. Gancia, Estimation of pKa using semiempirical molecular orbital methods. Part 1: Application to phenols and carboxylic acids, Quant. Struct.-Act. Relat. 21 (2002), pp. 457–472. doi:10.1002/1521-3838(200211)21:5<457::AID-QSAR457>3.0.CO;2-5.
   Web of Science ®Google Scholar
• P.H. Lee, S.N. Ayyampalayam, L.A. Carreira, M. Shalaeva, S. Bhattachar, R. Coselmon, S. Poole, E. Gifford, and F. Lombardo, In silico prediction of ionization constants of drugs, Mol. Pharm. 4 (2007), 498–512.
   PubMed Web of Science ®Google Scholar
• J.E. Donald, D.W. Kulp, and W.F. DeGrado, Salt bridges: Geometrically specific, designable interactions, Proteins Struct. Funct. Bioinf. 79 (2011), pp. 898–915. doi:10.1002/prot.22927.
   PubMed Web of Science ®Google Scholar
• D.A. Dougherty, The cation-π interaction, Acc. Chem. Res. 46 (2013), pp. 885–893. doi:10.1021/ar300265y.
   PubMed Web of Science ®Google Scholar
• M. Shalaeva, G. Caron, Y.A. Abramov, T.N. O’Connell, M.S. Plummer, G. Yalamanchi, K.A. Farley, G.H. Goetz, L. Philippe, and M.J. Shapiro, Integrating intramolecular hydrogen bonding (IMHB) considerations in drug discovery using ΔlogP as a tool, J. Med. Chem. 56 (2013), pp. 4870–4879. doi:10.1021/jm301850m.
   PubMed Web of Science ®Google Scholar
• P.W. Kenny, C.A. Montanari, I.M. Prokopczyk, J.F.R. Ribeiro, and G.R. Sartori, Hydrogen bond basicity prediction for medicinal chemistry design, J. Med. Chem. 59 (2016), pp. 4278–4288. doi:10.1021/acs.jmedchem.5b01946.
   PubMed Web of Science ®Google Scholar
• G.B. McGaughey, M. Gagné, and A.K. Rappé, π-Stacking interactions alive and well in proteins, J. Biol. Chem. 273 (1998), pp. 15458–15463. doi:10.1074/jbc.273.25.15458.
   PubMed Web of Science ®Google Scholar
• D.D. Boehr, A.R. Farley, G.D. Wright, and J.R. Cox, Analysis of the π-π stacking interactions between the aminoglycoside antibiotic kinase APH(3′)-IIIa and its nucleotide ligands, Chem. Biol. 9 (2002), pp. 1209–1217.
   PubMed Web of Science ®Google Scholar
• E. Persch, O. Dumele, and F. Diederich, Molecular recognition in chemical and biological systems, Angew. Chem. Int. Ed Engl. 54 (2015), pp. 3290–3327.
   PubMed Web of Science ®Google Scholar